Receive alerts
Market Cap:
$159.05 m
3.30 USD
52 weeks high
52 weeks low

Volition is a multi-national company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.

Volition's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.


Rethinking the approach to cancer

Nu.Q™ represents a powerful step-change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis.

  • Nu.Q™’s unique technology looks for very early ‘nucleosomic’ markers of cancer
  • Nu.Q™ uses an array of simple, cost-effective, and accurate blood tests
  • These tests identify early stage cells before the cancer spreads

Giving medical professionals increased diagnostic power

Nu.Q™ can reduce the strain on over-burdened healthcare systems

  • Early diagnosis informs and reassures patient

How it works

Cancer leads to irregular levels of uniquely structured nucleosomes in the blood. A nucleosome is a section of DNA wrapped around a core of proteins. Through a simple test, with a small amount of blood, we are able to detect those unique nucleosomes; and by measuring and analyzing them, our Nu.Q™ tests can identify patients who may have a cancer. This must be confirmed by follow up procedures - for example, for colorectal cancer a colonoscopy must be performed.

Colorectal Cancer

Volition’s initial Nu. Q™ products are focusing on colorectal cancer. Colorectal cancer is ranked second among all newly diagnosed cancers.

  • Patients with bowel cancer caught early (at stage I) have an average 97% five-year survival rate. Currently, fewer than one in ten people are diagnosed at stage I
  • If colorectal cancer is not caught until it has spread (stage IV), the chances of surviving five years or more falls to just 7%
  • Colorectal cancer is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and nearly 700,000 deaths worldwide

Mandated screening

In response to the findings on the benefits of early diagnosis, the EU and numerous other countries worldwide have mandated colorectal cancer screening programs. There are currently organised colorectal cancer screening programmes in 14 of the 28 EU states, with a further 10 states offering some form of public or privately accessible screening.

X Mandated 2

Colorectal Cancer Screening Triage Test

Volition’s first Nu.Q™ test is the Nu.Q™ colorectal cancer screening triage test. This test works in conjunction with the current standard screening test, the fecal immunochemical test (FIT), used in most colorectal cancer screening programs.

Streamlining the diagnostic process

The Nu.Q™ colorectal cancer screening triage test identifies patients who have received a false positive result on their FIT test. Approximately 95% of people who receive a positive FIT score do not have colorectal cancer due to the test’s detecting blood in stool, not cancer directly. Therefore, the Nu.Q™ colorectal cancer screening triage test aims to streamline the diagnostic process and ensure that fewer patients are referred for unnecessary colonoscopies.


Austin, Texas 

London, England 


Executive Team

Cameron Reynolds MBA
President & Chief Executive Officer

Cameron is an experienced entrepreneurial executive, with expertise in biotechnology companies. He has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises.

Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

Jake Micallef PhD MBA
Chief Scientific Officer

Jake is an experienced scientist with expertise in research and development and in the management of early stage biotechnical companies, including the manufacturing of biotechnology products and the establishment of manufacturing operations. Jake received his BSc in Biology and Chemistry, and his PhD in Physical Chemistry from King’s College London. In addition, he received his MSc in Chemical Pathology from St Thomas’ Hospital Medical School, and his MBA from Imperial College Management School.

David Vanston MBA FCCA
Chief Financial Officer

David has 20 years of financial management experience. Prior to Volition and Octo Telematics, David held positions as Vice President of Excorp Medical, Inc., an early-stage company, Chief Financial Officer for GrowHow Ltd and Vice President Europe, Finance for Monster Worldwide, Inc. David managed and oversaw the accounting, finance, tax, treasury, financial planning and analysis of the business.

David is a certified chartered accountant and holds an MBA from Warwick Business School.

Louise Day
Chief Marketing and Communications Officer

Louise brings more than 20 years of marketing, sales and leadership experience to her role at Volition. Since 2011, she has served as Director and Owner of Aculd Ltd, a strategic marketing consultancy specializing in healthcare. Formerly Louise worked in various roles at Reckitt Benckiser including some overseas posts in Paris and New York. She holds a Bachelor of Arts in Business Studies from Sheffield Hallam University.

Gaetan Michel PhD
Chief Executive Officer of Belgian Volition SPRL

Gaetan has over 10 years of experience in production management. Following the completion of his PhD in 2002, Gaetan joined AAT (Advanced Array Technology), a University of Namur spin-off company as project manager in proteomics. AAT later became EAT (Eppendorf Array Technology), part of the German Eppendorf Biotech company, where Gaetan became production manager and was involved in establishing production processes and equipment. From 2007 to 2010 he worked for KitoZyme, a global manufacturer of biopolymers of fungal origin with its core business in weight management, digestive and cardiovascular health.

Jason Terrell MD
Chief Medical Officer & Chief Executive Officer of Volition America, Inc.

Jason has expertise in clinical medicine and in laboratory diagnostics. He was educated at Hardin-Simmon University (Biochemistry) where he graduated Summa Cum Laude, also receiving the Holland Medal of Honor. He received his Doctor of Medicine from the University of Texas Medical School at Houston and affiliate MD Anderson Cancer Center.

Jason has a strong grounding in both medicine and more specifically in diagnostics and product commercialization.

Jasmine Kway PhD
Chief Executive Officer, Singapore Volition

Jasmine has a proven track record in achieving positive business results by developing strategic business alliances, identifying new markets, and developing business processes. As a thought leade in technology management and commercialization, she has worked with numerous health and regulatory bodies across Asia and has successfully comercialised technologies and expanded companies into the Asian markets.

Jasmine has a Bachelor of Engineering and a Doctor of Philosophy in Oceanography from the National University of Singapore.

Rod Rootsaert LLB
Corporate Secretary

Rod is an experienced legal and corporate secretary with over ten years’ experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several junior mining companies in the United Kingdom. Rod received a Bachelor of Laws degree from the University of Western Australia.

Scott Powell PhD
Executive Vice President, Investor Relations & Chief Financial Officer of Volition America, Inc.

Scott has nearly 20 years of experience in the U.S. capital markets and investor relations. Scott has served as Head of Investor Relations for four public companies, including Volition, and worked for several years as an investment banker. He earned his B.S. in Business Administration from Bryant University and his MA and PhD degrees from Brown University.

Dr. Mark Eccleston
Business Development Director

Dr Mark Eccleston is an enthusiastic and passionate biotechnology entrepreneur with over 20 years experience in the sector. He holds a PhD in Polymer Chemistry for biomedical applications and gained an MBA (entrepreneurship) from the University of Dundee in 2008.

Mark is the Managing Director of OncoLytika Ltd. a technical consultancy company working with international private and public limited companies operating in the diagnostics and therapeutic sectors as well as academia.

Dr Eccleston is the Business Development Director at Volition, a company developing next generation blood tests for early detection of cancer. Volition’s epigenetics based immunoassay approach to rapid, affordable cancer diagnostics is intended to revolutionise cancer screening and diagnosis. Mark coordinates the commercialisation of Volition’s Research Use kit range based on this proprietary Nucleosomics® technology platform.

Belgian Volition SPRL

22 Rue Phocas Lejeune
Parc Scientifique Crealys
5032 Isnes

Volition America Inc.

13215 Bee Cave Parkway
Galleria Oaks B, Suite 125
Austin, Texas 78738

Volition Diagnostics UK Ltd.

93-95 Gloucester Place


1 Scotts Road
#24-05 Shaw Centre

Investor Relations

Scott Powell
T: (646) 650-1351
[email protected]
Investor Relations

Edison Advisors
Tirth Patel
T: (646) 653-7035
[email protected]

Edison Advisors
Rachel Carroll
T: +44 (0) 20 3077 5711
[email protected]

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
[email protected]